Cargando…

Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience

Detalles Bibliográficos
Autores principales:	Suleman, Adam, Liu, Jiajia, Hicks, Lisa K., Drori, Adi Klil, Crump, Michael, Kridel, Robert, Prica, Anca, Berinstein, Neil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071115/ https://www.ncbi.nlm.nih.gov/pubmed/36453110 http://dx.doi.org/10.3324/haematol.2022.282014

Ejemplares similares

Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma
por: Zhao, Defeng, et al.
Publicado: (2014)

Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
por: Sun, Xuefei, et al.
Publicado: (2017)

P1223: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZRMA REGIMEN（ZANUBRUTINIB, RITUXIMAB, METHOTREXATE AND CYTARABINE)
por: Tang, Y.
Publicado: (2022)

P1160: METHOTREXATE IN COMBINATION WITH IBRUTINIB, THIOTEPA, RITUXIMAB (R-MTO) FOLLOWED BY AUTOLOGOUS STEM-CELL TRANSPLANT FOR PRIMARY CNS LYMPHOMA
por: Xing, LI-Jie, et al.
Publicado: (2023)

High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis
por: Li, Yufeng, et al.
Publicado: (2023)

P1145: PRELIMINARY RESULTS OF PENPULIMAB COMBINED WITH RMA(RITUXIMAB, METHOTREXATE, AND CYTARABINE) FOR NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Shen, Haorui, et al.
Publicado: (2023)

Whither thiotepa (for patients in the USA)?
por: Dardis, Christopher, et al.
Publicado: (2015)

Thiotepa in the treatment of advanced breast cancer.
por: Lyons, A. R., et al.
Publicado: (1965)

Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma
por: Dührsen, Ulrich, et al.
Publicado: (2021)

Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy
por: Hoffmann, Marc S., et al.
Publicado: (2021)

Cytarabine/dasatinib/rituximab: Reactivation of COVID-19 pneumonia : case report
Publicado: (2020)

Methotrexate and Cytarabine—Loaded Nanocarriers for Multidrug Cancer Therapy. Spectroscopic Study
por: Pentak, Danuta, et al.
Publicado: (2016)

Lomustine, methotrexate and cytarabine chemotherapy as a rescue treatment for feline lymphoma
por: Smallwood, Katherine, et al.
Publicado: (2020)

The Combined Thiotepa and Testosterone Treatment of Cancer of the Breast
por: Brown, I. Scott, et al.
Publicado: (1964)

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
por: Bravaccini, Sara, et al.
Publicado: (2020)

PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE
por: Di Folca, S., et al.
Publicado: (2022)

CD 5+ Peripheral B Cell Lymphoma With Transformation to CD 5+ Diffuse Large B Cell Lymphoma in the CNS: A Case Report Treated With Rituximab, High Dose Methotrexate, Cytarabine, and Intrathecal Methotrexate
por: Uczkowski, Dariusz, et al.
Publicado: (2022)

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
por: Shanafelt, Tait D., et al.
Publicado: (2022)

International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma
por: Khwaja, Jahanzaib, et al.
Publicado: (2022)

Virtual Healthcare for Older Adults: Accessibility, Perceptions and Benefits
por: Rigas, Christina, et al.
Publicado: (2023)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
por: Bega, Giulia, et al.
Publicado: (2021)

High-dose thiotepa-related neurotoxicity and the role of tramadol in children
por: Maritaz, Christophe, et al.
Publicado: (2018)

Rituximab/methotrexate: Lack of efficacy: case report
Publicado: (2022)

Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy
por: Yuen, Hiu Lam Agnes, et al.
Publicado: (2020)

In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program
por: Isaev, Keren, et al.
Publicado: (2022)

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)

Rituximab/bendamustine/cytarabine for transplant‐eligible patients with mantle cell lymphoma: A retrospective study
por: Shimizu, Yuki, et al.
Publicado: (2023)

Nucleoside transporter-guided cytarabine-conjugated liposomes for intracellular methotrexate delivery and cooperative choriocarcinoma therapy
por: Fei, Weidong, et al.
Publicado: (2021)

Novel Nanotherapeutic Systems Based on PEGylated Squalene Micelles for Enhanced In Vitro Activity of Methotrexate and Cytarabine
por: Craciun, Bogdan-Florin, et al.
Publicado: (2023)

Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma
por: Delphine, Lebon, et al.
Publicado: (2023)

ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
por: Takezaki, Tatsuya, et al.
Publicado: (2020)

Intravascular Large B Cell Lymphoma with CNS Involvement Successfully Treated with High-Dose Methotrexate and High-Dose Ara-C Based CNS-Directed Chemoimmunotherapy Alternating with Anthracycline Based Chemoimmunotherapy
por: Wang, Jing, et al.
Publicado: (2022)

Salvage chemotherapy with R-BAD (rituximab, bendamustine, cytarabine, and dexamethasone) for the treatment of relapsed primary CNS lymphoma
por: Cho, Min-Seok, et al.
Publicado: (2016)

Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
por: Tisi, Maria Chiara, et al.
Publicado: (2023)

Skeletal muscle density is an independent predictor of diffuse large B‐cell lymphoma outcomes treated with rituximab‐based chemoimmunotherapy
por: Chu, Michael P., et al.
Publicado: (2016)

Chemoimmunotherapy with rituximab, cyclophosphamide and prednisolone in IgM paraproteinemic neuropathy: evidence of sustained improvement in electrophysiological, serological and functional outcomes
por: Colchester, Nancy T. H., et al.
Publicado: (2020)

Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient
por: Camus, Vincent, et al.
Publicado: (2018)

The Use of Virtual Care in Patients with Hematologic Malignancies: A Scoping Review
por: Suleman, Adam, et al.
Publicado: (2022)

PB2315: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZR OR ZRM REGIMEN (ZANUBRUTINIB, RITUXIMAB, METHOTREXATE)
por: Teng, Yue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v6usforkul324vvjlcld93asaf